Low dose, oral lorazepam: a safe and effective adjuvant to antiemetic therapy.
Indian J Cancer
;
1991 Jun; 28(2): 108-13
Artigo
em Inglês
| IMSEAR
| ID: sea-50789
ABSTRACT
Twenty-five patients with acute nonlymphoblastic leukemia undergoing 41 cycles of chemotherapy with daunorubicin/cytosine arabinoside (ara-C) or with etoposide/ara-C received metoclopramide (MCP; 0.5 mg/kg 6 hourly i.v.) or MCP (same dose) plus oral lorazepam (1 mg/d) during and 24 hours following the chemotherapy as antiemetic medication. Control of vomiting was achieved is 55% (complete 5%, partial 50%) of the patients receiving MCP alone and in 100 percent (complete 76.1%; partial 23.8%) of those receiving MCP plus lorazepam (p less than 0.001). Eighteen of the 21 patients (85.7%) receiving MCP plus lorazepam opted for the same antiemetic regimen as compared to six of the 20 (30%) receiving MCP alone (p less than 0.01). One patient in each group developed mild sedation during the treatment. It is concluded that oral lorazepam is an effective and safe adjuvant to MCP for the control of vomiting during cancer chemotherapy.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Assunto principal:
Vômito
/
Feminino
/
Humanos
/
Masculino
/
Leucemia Mieloide Aguda
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Adjuvantes Farmacêuticos
/
Administração Oral
/
Adolescente
/
Adulto
Tipo de estudo:
Ensaio Clínico Controlado
Idioma:
Inglês
Revista:
Indian J Cancer
Ano de publicação:
1991
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS